Examkin

Soru

Zorluk: OrtaRheumatology and Immunology

A 26-year-old man comes to the clinic for a follow-up evaluation of chronic lower back pain. His symptoms began 2 years ago, are typically worse in the morning, and improve with exercise but not with rest. He often wakes up in the second half of the night due to the pain. Physical examination shows limited forward flexion of the lumbar spine with a modified Schober test of 2 cm. Magnetic resonance imaging of the sacroiliac joints demonstrates active osteitis indicative of bilateral sacroiliitis. Laboratory studies show a positive HLA-B27. A diagnosis of ankylosing spondylitis is established. The patient asks about the long-term therapeutic plan, understanding that initial treatments might not be fully effective over time.

Arrange the following interventions and clinical protocols in the correct chronological sequence for the escalation of therapy in this patient, assuming an inadequate clinical response to each prior step.

  1. 1Initiate maximum-dose continuous nonsteroidal anti-inflammatory drug (NSAID) therapy
  2. 2Screen for latent tuberculosis and chronic viral hepatitis infections
  3. 3Initiate biologic therapy with a tumor necrosis factor (TNF) alpha inhibitor
  4. 4Transition therapy to an interleukin-17 (IL-17) inhibitor

Cevap

The correct chronological sequence of escalation is to first maximize NSAID therapy, then screen for latent infections upon NSAID failure, subsequently initiate a TNF alpha inhibitor, and finally switch to an IL-17 inhibitor if the TNF inhibitor is ineffective.
The management of ankylosing spondylitis follows a strict, evidence-based algorithm. It begins with continuous NSAIDs as the first-line therapy, which differs from rheumatoid arthritis where early DMARDs are initiated. If NSAIDs fail to control axial symptoms, the patient must be escalated to a biologic agent, bypassing conventional synthetic DMARDs (like methotrexate), which only work for peripheral joint involvement. Before any biologic agent is started, mandatory screening for latent tuberculosis (TB) and chronic hepatitis is required, as immunosuppression can lead to fatal reactivation. Once cleared, a TNF alpha inhibitor is the preferred initial biologic. Should the patient have an inadequate response or lose efficacy over time, guidelines recommend switching to an alternative biologic class, most commonly an IL-17 inhibitor.

Adım Adım Çözüm

1
Identify the diagnosis and first-line therapy.
The patient has active axial ankylosing spondylitis. The first-line pharmacological treatment is continuous NSAID therapy combined with physical therapy.
NSAIDs are highly effective for symptom control in early axial disease and are the required first step before insurance or clinical guidelines permit biologic initiation.
2
Determine the necessary prerequisites for escalating therapy after NSAID failure.
Screening for latent tuberculosis (via interferon-gamma release assay) and viral hepatitis must be performed.
Because conventional synthetic DMARDs like methotrexate are ineffective for purely axial disease, the patient will need a biologic DMARD. Biologics significantly increase the risk of reactivating granulomatous and viral infections.
3
Select the appropriate second-line therapy.
Initiate a TNF alpha inhibitor (e.g., adalimumab, etanercept).
TNF inhibitors are the standard evidence-based second-line agents for axial spondyloarthritis in patients who have failed NSAIDs and have negative infectious screening.
4
Determine the next pharmacological step if the initial biologic fails.
Switch to an IL-17 inhibitor (e.g., secukinumab).
When a patient fails to respond to a TNF inhibitor, escalating to a different mechanistic class, such as an IL-17 inhibitor, is the recommended clinical pathway.

Anahtar Kavram

Pharmacological escalation and pre-biologic safety screening in the management of ankylosing spondylitis
Tahmini Süre:1m 15s
Bu soruyu puanla

Konular

Rheumatology and Immunology

Bu konudan daha fazla soru